CA2947736C - Vmat2 inhibitors for the treatment of hyperkinetic movement disorders - Google Patents

Vmat2 inhibitors for the treatment of hyperkinetic movement disorders Download PDF

Info

Publication number
CA2947736C
CA2947736C CA2947736A CA2947736A CA2947736C CA 2947736 C CA2947736 C CA 2947736C CA 2947736 A CA2947736 A CA 2947736A CA 2947736 A CA2947736 A CA 2947736A CA 2947736 C CA2947736 C CA 2947736C
Authority
CA
Canada
Prior art keywords
dimethoxy
htbz
hexahydro
ester
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2947736A
Other languages
English (en)
French (fr)
Other versions
CA2947736A1 (en
Inventor
Christopher F. O'Brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CA2947736A1 publication Critical patent/CA2947736A1/en
Application granted granted Critical
Publication of CA2947736C publication Critical patent/CA2947736C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2947736A 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders Active CA2947736C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
CA2947736A1 CA2947736A1 (en) 2015-11-12
CA2947736C true CA2947736C (en) 2023-04-18

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2947736A Active CA2947736C (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Country Status (24)

Country Link
US (3) US20170071932A1 (https=)
EP (3) EP3139925B1 (https=)
JP (4) JP6635945B2 (https=)
KR (5) KR20200133003A (https=)
CN (3) CN106456629A (https=)
AU (1) AU2015256012B2 (https=)
CA (1) CA2947736C (https=)
CY (1) CY1125058T1 (https=)
DK (2) DK3936130T3 (https=)
ES (2) ES2976207T3 (https=)
FI (1) FI3936130T3 (https=)
HR (2) HRP20240459T1 (https=)
HU (2) HUE057839T2 (https=)
IL (1) IL248745B (https=)
LT (2) LT3936130T (https=)
MX (1) MX387625B (https=)
NZ (1) NZ725826A (https=)
PL (2) PL3936130T3 (https=)
PT (2) PT3139925T (https=)
RS (2) RS65359B1 (https=)
RU (1) RU2753740C2 (https=)
SI (2) SI3139925T1 (https=)
SM (2) SMT202400199T1 (https=)
WO (1) WO2015171802A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193767A (en) * 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
EP3568394A1 (en) 2017-01-10 2019-11-20 Sandoz AG Crystalline valbenazine free base
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
CN110678181A (zh) * 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
CA3081709A1 (en) 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
EP3784237B1 (en) * 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MA55893A (fr) * 2019-05-09 2022-03-16 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2081929T3 (pl) * 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN104684555A (zh) * 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
NZ760790A (en) * 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Also Published As

Publication number Publication date
EP4389227A3 (en) 2024-09-04
JP2017514850A (ja) 2017-06-08
CN106456629A (zh) 2017-02-22
ES2976207T3 (es) 2024-07-26
EP3139925B1 (en) 2021-12-01
JP2024153782A (ja) 2024-10-29
EP3936130A1 (en) 2022-01-12
IL248745B (en) 2022-07-01
PT3139925T (pt) 2022-01-26
ES2904526T3 (es) 2022-04-05
CN112741835A (zh) 2021-05-04
MX387625B (es) 2025-03-18
RU2016147523A (ru) 2018-06-08
JP2019218407A (ja) 2019-12-26
SMT202400199T1 (it) 2024-07-09
IL248745A0 (en) 2017-01-31
CA2947736A1 (en) 2015-11-12
HUE057839T2 (hu) 2022-06-28
CY1125058T1 (el) 2023-06-09
NZ725826A (en) 2023-05-26
SMT202200193T1 (it) 2022-07-21
AU2015256012A1 (en) 2016-11-24
PT3936130T (pt) 2024-04-17
US20200101063A1 (en) 2020-04-02
DK3936130T3 (da) 2024-03-25
RU2753740C2 (ru) 2021-08-23
KR20200133003A (ko) 2020-11-25
HRP20220025T1 (hr) 2022-04-01
DK3139925T3 (da) 2021-12-20
SI3139925T1 (sl) 2022-04-29
RS65359B1 (sr) 2024-04-30
LT3139925T (lt) 2022-01-25
KR20160147044A (ko) 2016-12-21
RS62782B1 (sr) 2022-01-31
MX2016014429A (es) 2017-04-06
JP2021191799A (ja) 2021-12-16
EP4389227A2 (en) 2024-06-26
US20210196702A1 (en) 2021-07-01
HRP20240459T1 (hr) 2024-06-21
JP6635945B2 (ja) 2020-01-29
HUE066361T2 (hu) 2024-07-28
EP3139925A1 (en) 2017-03-15
WO2015171802A1 (en) 2015-11-12
KR20240011255A (ko) 2024-01-25
PL3936130T3 (pl) 2024-06-10
KR20220140647A (ko) 2022-10-18
AU2015256012B2 (en) 2020-07-23
RU2016147523A3 (https=) 2018-12-28
PL3139925T3 (pl) 2022-03-21
FI3936130T3 (fi) 2024-04-23
KR20250029267A (ko) 2025-03-04
LT3936130T (lt) 2024-04-25
SI3936130T1 (sl) 2024-05-31
CN112741836A (zh) 2021-05-04
EP3936130B1 (en) 2024-02-14
US20170071932A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
CA2947736C (en) Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
WO2022060978A1 (en) Methods of treating parkinson's disease and related disorders with pde10a inhibitors
US20080070952A1 (en) Inhibition or Treatment of Dyskinesia
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200428

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502